Long-term efficacy of specific immunotherapy on house dust mite-induced allergic rhinitis in China

Otolaryngology - Head and Neck Surgery (United States)

Volumn 149, Issue 1, 2013, Pages 40-46

  Peng, Hua ^a,b   Wei Li, Chun ^c   Lin, Zhi Bin ^a   Li, Tian Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Allergic rhinitis; Asthma; House dust mite; Long term efficacy; Specific immunotherapy

Indexed keywords

IMMUNOGLOBULIN E;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; CHINA; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOPHAGOIDES; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; RESCUE MEDICATION SCORE; SPECIFIC IMMUNOTHERAPY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VISUAL ANALOG SCALE;

ALLERGIC RHINITIS; ASTHMA; HOUSE DUST MITE; LONG-TERM EFFICACY; SPECIFIC IMMUNOTHERAPY;

ADOLESCENT; ADULT; ANIMALS; ASTHMA; CHILD; CHINA; COHORT STUDIES; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883215019     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599813485222     Document Type: Article

References (23)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl):8-160.
2. Broide DH. Allergic rhinitis: pathophysiology. Allergy Asthma Proc. 2010;31:370-374.
3. Bernstein JA. Allergic and mixed rhinitis: epidemiology and natural history. Allergy Asthma Proc. 2010;31:365-369.
4. Arbes SJ Jr, Gergen PJ, Elliott L, et al. Prevalence of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116:377-383.
5. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1-S84.
6. Zhang L, Han D, Huang D, et al. Prevalence of self-reported allergic rhinitis in eleven major cities in china. Int Arch Allergy Immunol. 2007;149:47-57.
7. Zhao J, Bai J, Shen K, et al. Self-reported prevalence of childhood allergic diseases in three cities of China: a multicenter study. BMC Public Health. 2010;10:551.
8. Li F, Zhou Y, Li S, et al. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. BMC Public Health. 2011;11:437.
9. Li J, Sun B, Huang Y, et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009;64:1083-1092.
10. Kong WJ, Chen JJ, Zheng ZY, et al. Prevalence of allergic rhinitis in 3-6-year-old children in Wuhan of China. Clin Exp Allergy. 2009;39:869-874.
11. Zhang YM, Zhang J, Liu SL, et al. Prevalence and associated risk factors of allergic rhinitis in preschool children in Beijing. Laryngoscope. 2013;123:28-35.
12. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341:468-475.
13. Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251-256.
14. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943-948.
15. Madonini E, Agostinis F, Barra R, et al. Long-term and preventive effects of allergen-specific sublingual immunotherapy: a restrospective multicenter study. Int J Immunopathol Pharmacol. 2003;16:73-79.
16. Passalacqua G, Canonica GW. Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy. 2002;57:275-276.
17. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143-178.
18. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317-324.
19. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104:534-540.
20. Guerra S, Sherrill DL, Martinez FD, et al. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109:419-425.
21. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year followup study of college students. Allergy Proc. 1994;15:21-25.
22. Di Lorenzo G, Mansueto P, Pacor ML, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;123:1103-1110.
23. Fujimura T, Yonekura S, Horiguchi S, et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2- year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol. 2011;139:65-74.